Beijing Bohui Innovation Biotechnology Group Co., Ltd. ("Bohui Group"), founded in 2001, has evolved into a high-tech biomedical enterprise that integrates R&D, production, sales, and after-sales service into a comprehensive system. Headquartered in Zhongguancun Life Science Park in Beijing, the company operates a 40,000-square-meter integrated R&D center. In May 2012, Bohui Group was listed on the Shenzhen Stock Exchange ChiNext (Stock Code: 300318).

In the field of inspection and testing, Bohui Group possesses strong independent R&D capabilities. Its fully automated nucleic acid detection products based on microfluidic technology are acclaimed as a "laboratory on a chip". Additionally, through the wholly-owned acquisition of Advion, a US-based company, Bohui Group has concentrated its efforts on the application of mass spectrometry analysis within the life sciences sector, offering customers outstanding mass spectrometry products and exceptional user experience.

Within the strategic emerging biopharmaceutical industry, Bohui Group currently owns two blood product manufacturing facilities in Shijiazhuang City (Hebei Province) and Shantou City (Guangdong Province). It is also constructing a new-generation blood product manufacturing facility in Qujing City (Yunnan Province) and Hohhot City (Inner Mongolia Autonomous Region) respectively, while additionally holding a vaccine manufacturing facility in Langfang City (Hebei Province).